
FDA adviser resigns over approval of new Alzheimer's drug
CNN
A member of an FDA advisory committee said Wednesday he had resigned over the agency's approval of a new Alzheimer's drug.
The FDA approved aducanumab, to be sold under the brand name Aduhelm, this week over the objections of its advisory Peripheral and Central Nervous System Drugs Advisory Committee. Mayo Clinic neurologist Dr. David Knopman told CNN Wednesday he had resigned from the committee in protest.More Related News

More photos from Epstein’s estate released by House Democrats as deadline to release DOJ files looms
Democrats on the House Oversight Committee released photos from Jeffrey Epstein’s estate Thursday — the latest in a series of intermittent disclosures that have fueled significant political intrigue in recent weeks about who may have been associated with the convicted sex offender.












